Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed Phase 2Phase 3 Interventional

Improving Safety by Basic Computerizing Outpatient Prescribing

NCT01091038
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Basic Clinical Decision Support, Routine Care
Other
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
228 participants
Timeline
2001 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Phase 3 Interventional Results available

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer

NCT00305643
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pain
Interventions
Capecitabine, Celecoxib, Radiation Therapy, Placebo
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Santa Rosa, California • Grand Rapids, Michigan • Kalamazoo, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

NCT05787834
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Cancer, Lung Cancer
Interventions
Best Practice, Medical Device Usage and Evaluation, Respiratory Muscle Training, Survey Administration
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 1 Interventional

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

NCT04412616
View directory record Official record
Conditions
Advanced EGFR Positive Solid Tumor
Interventions
ZZ06
Biological
Lead sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Fairway, Kansas • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Medication, Weight Gain and GI Hormones

NCT00384332
View directory record Official record
Conditions
Bipolar Depression
Interventions
orally-disintegrating olanzapine, regular olanzapine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting Phase 1 Interventional

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Not applicable Interventional

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

NCT05812274
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813
View directory record Official record
Conditions
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Interventions
Lenvatinib, ABBV-324
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy

NCT00001874
View directory record Official record
Conditions
Cardiovascular Disease, Healthy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 1:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

NCT01439152
View directory record Official record
Conditions
Oncology
Interventions
BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 23, 2026, 1:32 AM EDT
Not listed Phase 1 Interventional

Post IVIG Medication in Children With Immune Thrombocytopenia

NCT04741139
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Acetaminophen and Diphenhydramine Only Product
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience

NCT02320175
View directory record Official record
Conditions
Communication
Interventions
Patient and Family Centered I-PASS
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
6,478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • San Francisco, California • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Not applicable Interventional Results available

Effects of SinuSonic on Psychological and Physical Well-Being

NCT06268730
View directory record Official record
Conditions
Nasal Congestion and Inflammations, Sinus Congestion Chronic
Interventions
SinuSonic
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Surabgene Lomparvovec (ABBV-RGX-314), Ranibizumab Control
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
55
States / cities
Mesa, Arizona • Sun City, Arizona • Campbell, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional

Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

NCT03108911
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Best Practice, Biospecimen Collection, Dietary Intervention, Laboratory Biomarker Analysis
Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine, Venetoclax, Azacitidine, Matching Placebo for PVEK
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications

NCT07380412
View directory record Official record
Conditions
ADHD, Sleep Disturbance, Brain Fog
Interventions
Stasis Daytime and Nighttime, Placebo
Dietary Supplement
Lead sponsor
Outliers, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 23, 2026, 1:32 AM EDT
Completed No phase listed Observational

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

NCT04770922
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 23, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
View directory record Official record
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 23, 2026, 1:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

NCT06892522
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
15
States / cities
Duarte, California • Irvine, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 1:32 AM EDT